vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $17.08 and traded as low as $16.60. vTv Therapeutics shares last traded at $16.99, with a volume of 1,403 shares trading hands.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on VTVT shares. Wall Street Zen started coverage on shares of vTv Therapeutics in a report on Wednesday, April 16th. They set a "sell" rating on the stock. HC Wainwright began coverage on vTv Therapeutics in a research report on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price on the stock.
View Our Latest Report on VTVT
vTv Therapeutics Price Performance
The firm's 50-day moving average price is $16.90 and its 200-day moving average price is $17.39. The stock has a market cap of $53.50 million, a P/E ratio of -5.57 and a beta of 0.58.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.04).
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of VTVT. Connective Capital Management LLC purchased a new stake in vTv Therapeutics in the 1st quarter valued at about $162,000. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the fourth quarter valued at approximately $25,000. Finally, Geode Capital Management LLC boosted its holdings in shares of vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,327 shares during the period. Hedge funds and other institutional investors own 17.51% of the company's stock.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Read More
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
